NCT03561298View on ClinicalTrials.gov

A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

June 7, 2018

Study Completion Date

July 2, 2018

Conditions
Healthy Subjects
Interventions
DRUG

BGB-3111 and Drug Cocktail

BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)

Trial Locations (1)

32117

Covance Clinical Research Unit, Daytona Beach

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03561298 - A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects | Biotech Hunter | Biotech Hunter